1David S H.Bell: a comparison of agents used to manage type 2 biabetes mellitus,need for reappraisal of traditional approaches[J]. Treat Endcr,2004,3(2): 67-76.
3Maller G,Satoh Y,Geisen K. Extrapancreatic effects of sulfonylureas: a comparison between glimepiride and conventional sulfonylureas[J]. Diabetes Res Clin Pract,1995,28(Suppl): 115-121.
二级参考文献10
1Muller G,Satoh Y,Geisen K.Extrapancreatic effects of sulfonylureas: a comparison between glimepiride and conventional sulfonylureas[].Diabetes Research and Clinical Practice.1995
2Draeger KE,Wernicke-Panten K,Lomp HJ,et al.Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride ( Amaryl ): a double-blind comparison with glibenclamide[].Hormone and Metabolic Research.1996
3Campbell RK.Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus[].Annals of Pharmacotherapy.1998
4Rosenstock J,Schneider J,Samols E,et al.Glimepiride a new oncedaily sulfonylurea.A double-blind placebo-controlled study of NIDDM patients[].Diabetes Care.1996
5Kramer W,Muller G,Girbig F,et al.Differential interaction ofglimepiride and glibenclamide with theβ- cell sulfonylurea receptor.Photoaffinity labeling of a65Kda protein by[3H] glimepiride[].Biochimica et Biophysica Acta.1994
6Muller G,Hartz D,Punter J,et al.Differential interaction of glimepiride and glibenclamide with the -cell sulfonylurea receptor.I . Binding characteristics[].Biochimica et Biophysica Acta.1994
7Ozaki Y,Yatomi Y,Kume S.Effects of oral hypoglycemic agents on platelet functions[].Biochemical Pharmacology.1992
8Muller G,Wied S,Wetekam EM,et al.Stimulation of glucose utilization in 3T3 adipocytes and rat diaphragm in vitro by the sulfonylurea glimepiride and glibenclamide, is correlated with modulations of the cAMP regulatory cascade[].Biochemical Pharmacology.1994
9Goldberg RB,Schneider J,Holvey SM,et al.A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents[].Diabetes Care.1996
10Yamazaki H,Tabate S.Sex difference in pharmacokinetics of the novel sulfonylurea antidiabetic glimepiride in rats[].Arzneimittel Forschung.1993
3Saenz A, Fernandez-Esteban 1, Mataix A, et al. Metformin monotherapy for type 2 diabetes mellitus[J]. Cochrane Database Syst Rev, 2005,20(3): CD002966.
4Eurich DT, McAlister FA, Blackburn DF, et al. Benefits and harms of antidiabetie agents in patients with diabetes and heart failure: systematic review[J]. Bri Med J, 2007, 335(7618): 497.
5Foretz M, Hebrard S, Leclerc J, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state[J]. J Clin Invest, 2010, 120(7): 2355-2369.
6Sarabia V, Lam L, Burdett E, et al. Glucose transport in human skeletal muscle cells in culture. Stimulation by insulin and metformin[J]. J Clin Invest, 1992, 90(4): 1386-1395.
7Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action[J]. J Clin Invest, 2001, 108(8): 1167-1174.
8Mannueei E, Tesi F, Bardini G, et al. Effects of metformin on glucagon- like peptide-1 levels in obese patients with and without type 2 diabetes[J]. Diabetes Nutr Metab, 2004, 17(6): 336-342.
9UK Prespective Diabetes Study Group. Effect of intensive blood glucose control with metformin on complication in overweight patients with type 2 diebetes(UKPDS 34)[J]. Lancet, 1998, 352(9131): 854-865.
10Ong CR, Molyneaux LM, Constantino MI, et al. Long-term efficacy of metformin ther~ipy in nonobese individuals with type 2 diabetes[J]. Diabetes Care, 2006, 29(11): 2361-2364.
